Real-World Use of Ceftazidime–Avibactam for Carbapenem-Resistant Enterobacterales Infections in Children: A 7-Year Cohort From a Latin American Referral Center

Clicks: 11
ID: 332362
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #99 of 145 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 145 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Pediatric data on ceftazidime-avibactam (CAZ-AVI) for carbapenem-resistant Enterobacterales (CRE) infections remain limited, particularly in Latin America, where KPC-producing organisms are endemic. We describe the clinical characteristics, microbiological profile, and outcomes of children with CRE infections treated with CAZ-AVI at a tertiary referral center in Colombia. Methods We conducted a retrospective cohort study of children younger than 18 years with clinically significant CRE infections treated with CAZ-AVI between January 2018 and June 2025. Clinical, microbiological, treatment, and outcome data were collected. The primary outcome was clinical response at the end of therapy. Results Forty-three patients were included (median age, 11 years [IQR, 6–15]); 25 patients (58%) were immunocompromised, 29 (67%) required PICU admission, and 16 (37%) presented with septic shock. Klebsiella pneumoniae was the predominant pathogen (33 patients, 77%), and KPC was the most common carbapenemase detected (39 patients, 91%). Clinical improvement within 72 hours occurred in 40 patients (93%), with a median time to response of 2 days (IQR, 2–3). Overall, 40 patients (93%) achieved clinical cure. The estimated 30-day survival probability was 95.3% (95% CI, 88.8–100), recurrence occurred in 3 patients (7%), and no treatment-related adverse events were documented. Conclusion In this real-world pediatric cohort from a KPC-endemic setting, CAZ-AVI was associated with favorable clinical outcomes and good tolerability. These findings support its role as an important therapeutic option for pediatric CRE infections and underscore the importance of mechanism-guided antimicrobial management.
Reference Key
openalex_W7221810023 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maria Gabriela Novoa Villada, Andrea Restrepo, Mónica Trujillo-Valencia, Ana Maria Viana, Manuela Arbeláez Gómez, Libia María Rodríguez Padilla, Alejandro Díaz
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag109
URL
https://doi.org/10.1093/jpids/piag109
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.